NEWS
News Articles
Moonlight Therapeutics completes pre-IND meeting with FDA
Moonlight Therapeutics Completes Pre-IND Meeting With FDA for MOON101 for Peanut Allergy MOON101 is Moonlight’s lead program for treating peanut allergy using a dermal stamp Moonlight Therapeutics, Inc., a biotechnology company developing targeted treatments for food allergies, announced today it successfully completed a pre-Investigational New Drug Application (pre-IND) meeting with the U.S. Food and Drug…
Read MoreGeoVax Announces $10 Million Private Placement
ATLANTA, GA, January 14, 2022 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 707,484 shares of common stock, 2,360,000 pre-funded…
Read MoreCMS’ Attempt to Restrict Patient Access to Alzheimer’s Drug Sets “Dangerous and Far-Reaching” Precedent
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS) proposed National Coverage Determination (NCD) to restrict coverage for drugs used to treat patient suffering from Alzheimer’s: “The announcement by CMS sets a dangerous and far-reaching precedent for…
Read MoreGeoVax Appoints Dr. Kelly McKee as Chief Medical Officer
ATLANTA, GA, January 11, 2022 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H., to serve as the Company’s Chief Medical Officer (CMO). Dr. McKee brings over 30 years of experience in research and development, with…
Read MoreAmgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs
Amgen wants its future drugs to be multispecific, and so the biopharmaceutical company selected Generate Biomedicines for a $1.9 billion biobucks deal to initially create five programs across several diseases. The pair announced the deal Thursday morning, which includes $50 million upfront for the initial five program, with an option to collaborate on five more. Amgen will pay…
Read MoreGEORGIA TREND NAMES MARIA THACKER GOETHE AS ONE OF THE “100 MOST INFLUENTIAL GEORGIANS” IN 2022
ATLANTA, GA – Georgia Trend Magazine named Maria Thacker Goethe, Chief Executive Officer at Center for Global Health Innovation (The Center) and President & CEO of Georgia Bio, as one of the 100 Most Influential Georgians in 2022 for her work advancing Georgia as a top bioscience and MedTech hub. The Center just announced the…
Read More